Ensera, Argonaut Ink Combination Product Supply Deal

Ensera, a contract development and manufacturing organization (CDMO) specializing in final assembly and secondary packaging for drug delivery systems, began a new strategic partnership with Argonaut Manufacturing Services, a U.S.-based sterile fill-and-finish CDMO.

The collaboration merges aseptic fill-finish with device assembly and packaging services. It aims to simplify supply chains. Redice operational risk, and speed production timelines.

Argonaut offers aseptic fill-finish of vials, syringes, and cartridges using Annex 1 compliant isolator filling lines, as well as analytical testing and stability studies. Ensera complements these with final assembly of drug delivery devices, labeling, secondary packaging, kitting, serialization, sterilization management, and testing for vials and drug delivery devices.

The duo believes the partnership lets customers benefit from a streamlined quotation process covering both companies’ services before beginning a project. Projects that contract both companies will have closely coordinated project management to support aligned fill-and-finish device assembly activities for all development and manufacturing stages.

Argonaut completed an audit of Ensera’s U.S. facility and approved it as a critical supply chain partner. The partnership addresses several growing challenges in the combination product landscape, supply chain fragmentation, constrained capacity for mid-market programs, and increasing pressure to accelerate timelines for specialty biologics and biosimilars.

Comments from Ensera & Argonaut

Jason Anderson, CEO, Ensera: “This partnership reflects a shared focus on supporting the needs of pharmaceutical companies developing complex combination products, particularly in low to mid-volume scenarios where flexibility and coordination are essential. By aligning our device assembly and packaging expertise with Argonaut’s fill-finish capabilities, we are making it easier for customers to navigate critical transition points, reduce risk, and maintain momentum as their products progress toward commercialization.”

Rick Hancock, CEO, Argonaut: “More than ever, our clients are focused on developing their products in conjunction with autoinjectors to improve accessibility for patients. While this is a commendable goal, it adds complexity to supply chains. This partnership with Ensera eases that burden for sponsors. Just as our clients are focused on improving the patient experience, Argonaut is focused on improving our clients’ experience.”